Osteoporosis is often called the “silent disease” because bone
loss occurs without symptoms. It is characterized by low bone mass and
micro-architectural deterioration of bone tissue, leading to bone fragility
and a consequent increase in risk of fracture. Global osteoporosis market is
expected to reach 16 Billion by 2015. This significant growth is primarily
attributed to strong treatment options currently available in the market as
well as strong pipeline products. The increase in the prevalence of
osteoporosis among the female population is the principal driver of the
osteoporosis market and will continue to be in the future.
Fosamax was the undisputed leading product in the history of global
osteoporosis drug market till 2007. It has a market share of nearly 37% in
2007 but, declined to 5% by 2015 due to patent expiry and competition from
cheaper generics. Boniva and Evista were leading the osteoporosis market till
2010 but the dynamics of osteoporosis market is expected to change by 2011 as
Prolia is going to be introduced in the market. It is predicted that Prolia
will lead the market with nearly 45% share by 2015.
The osteoporosis market offers multiple opportunities for current and future
market players. In addition to increasing awareness, diagnosis and treatment,
there is the need to develop new drugs that promote bone building. While the
market awaits new growth, driven by the launch of several promising pipeline
drugs, including Amgen' s Prolia (denosumab), companies are looking for
innovative ways to maximize revenues from their products nearing the end of
their lifecycles.
Report Details
“Global Osteoporosis Market & Drugs Analysis 2010 - 2015” report
published by Renub Research provides an in-depth analysis of the past, present
and future prospects. The report has been researched at source globally and
features latest available data covering:
Global Osteoporosis Market (2009 to 2015)
Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin)
market and market share data of (2006 to 2014)
Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva,
Evista, Forteo, Viviant/Conbriza, Miacalcin, Prolia) sales and market share
data of 2007 to 2015
Six Countries (USA, European Union, Japan, China, India, Korea)
Osteoporosis market share data of (2009 to 2015)
Six Countries (USA, European Union, Japan, China, India, Korea)
Osteoporosis market data of (2005 to 2015)
Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis -
Revenue in Osteoporosis Market (2007 to 2010), Strength & Weakness in
Osteoporosis Market
Research Highlights
Global Osteoporosis drug market is expected to reach the figure of US$ 16
Billion by 2015
United States Osteoporosis drug market was nearly US$ 5 Billion in 2010
United States & China together is expected to control 61% market share in
osteoporosis drug market by 2015
Although SERM is increasing its market share year on year but
Bisphosphonates will continue to dominate the osteoporosis drug class segment
with 56% in 2014
Prolia will lead the Osteoporosis drug market with 45% share by 2015
Data Sources
Information and data in this report has been collected from various printable
and non-printable sources like Trade Journals, White papers, News websites,
Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 100 paid
databases.
Table of Contents
Table of Contents
1. Executive Summary
2. Global Osteoporosis Market
3. Global Osteoporosis Market Share (2007 - 2015)
3.1. By Drug Class - Osteoporosis Market Share & Forecast
3.2. By Drug Market Share - Osteoporosis Market Share & Forecast
3.3. By Country (USA, European Union, Japan, China, India, Korea) -
Osteoporosis Drug Market Share & Forecast
4. By Country - Osteoporosis Market & Forecast (2008 - 2015)
4.1. United States Osteoporosis Market & Forecast
4.2. European Union Osteoporosis Market & Forecast
Table 9 1: Osteoporosis - Drugs Cost Comparison (US$) in 1 Year
Global Osteoporosis Market & Drugs Analysis 2010 - 2015 published by Renub Research in September 1, 2011. This report consists of 72 Pages and the price starts from US $ 950.
